The Technical Analyst
Context Therapeutics Inc. [CNTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Context Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.68% $1.410
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 22.51 mill |
| EPS: | -1.500 |
| P/E: | -0.940 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 15.97 mill |
| Avg Daily Volume: | 0.0568 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.940 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.16x |
| Company: PE -0.940 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.905 (-35.81%) $-0.505 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.288 - 1.532 ( +/- 8.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-21 | Minai-azary Jennifer Lynn | Buy | 160 115 | Stock Option (right to buy) |
| 2024-03-21 | Levit Alex C. | Buy | 153 515 | Stock Option (right to buy) |
| 2024-03-21 | Lehr Martin A. | Buy | 291 402 | Stock Option (right to buy) |
| 2023-05-31 | Kantoff Philip W. | Buy | 25 000 | Stock Option (right to buy) |
| 2023-05-31 | West Linda | Buy | 25 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 72 transactions |
| Buy: 4 162 098 | Sell: 2 098 089 |
Forecast:
16:00 - $1.395
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.395
Forecast 2: 16:00 - $1.395
Forecast 3: 16:00 - $1.395
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.410 (3.68% ) |
| Volume | 0.0240 mill |
| Avg. Vol. | 0.0568 mill |
| % of Avg. Vol | 42.23 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CNTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-04-01 07:30:00 - Press Release
Context Therapeutics Submits Ind Application To Evaluate Ctim-76 In Claudin 6-positive Cancers
Important regulatory milestone supports next phase of ctim-76 development important regulatory milestone supports next phase of ctim-76 development
2024-03-21 07:43:00 - Press Release
Context Therapeutics Reports Full Year 2023 Operating And Financial Results
Ctim-76 ind filing on track for late march 2024 cash and cash equivalents of $14.4 million as of december 31, 2023 company expects its cash and cash equivalents will continue to fund operations into late 2024 philadelphia, march 21, 2024 (globe newswire) -- context therapeutics inc. (“context” or the “company”) (nasdaq: cntx), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended december 31, 2023, and reported on recent and upcoming business highlights. “during the fourth quarter of 2023, context continued to advance our lead clinical candidate, ctim-76, a claudin 6 ("cldn6”) x cd3 bispecific antibody, toward a first-in-human clinical study.
2023-11-09 16:15:00 - Press Release
Context Therapeutics Reports Third Quarter 2023 Operating And Financial Results
Ctim-76 ind filing on track for late q1 2024 cash and cash equivalents of $21.7 million as of september 30, 2023 company expects its cash and cash equivalents will continue to fund operations into late 2024 philadelphia, nov. 09, 2023 (globe newswire) -- context therapeutics inc. (“context” or the “company”) (nasdaq: cntx), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended september 30, 2023, and reported on recent and upcoming business highlights. “during the third quarter of this year, context continued to advance our lead clinical candidate, ctim-76, a claudin 6 ("cldn6”) x cd3 bispecific antibody, toward a first-in-human clinical study.
2023-09-27 09:00:00 - Press Release
Context Therapeutics Announces Acceptance Of Abstract To Be Presented At The Society For Immunotherapy Of Cancer's (sitc) 38th Annual Meeting
Philadelphia, sept. 27, 2023 (globe newswire) -- context therapeutics inc. (“context” or the “company”) (nasdaq: cntx), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the company's preclinical asset, ctim-76, a claudin 6 x cd3 bispecific antibody will be presented at the society for immunotherapy of cancer's (sitc) 38th annual meeting taking place november 3-5, 2023, at the san diego convention center in san diego, ca.
2023-08-09 16:10:00 - Press Release
Context Therapeutics Reports Second Quarter 2023 Operating And Financial Results
Company expects its cash and cash equivalents will continue to fund operations into late 2024 cash and cash equivalents of $25.1 million as of june 30, 2023 ctim-76 ind filing on track for q1 2024 philadelphia, aug. 09, 2023 (globe newswire) -- context therapeutics inc. (“context” or the “company”) (nasdaq: cntx), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended june 30, 2023, and reported on recent and upcoming business highlights. “during the second quarter of this year, context continued development of our preclinical asset ctim-76, a claudin 6 ("cldn6”) x cd3 bispecific antibody.
Latest News
2023-11-10 08:16:04 - Proactive Investors
Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024
Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, toward a first-in-human clinical study. The company said it remains on track to file an Investigational New Drug (IND) for CTIM-76 with the US Food and Drug Administration in the first quarter of 2024.
2023-10-31 10:12:59 - Proactive Investors
Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment
Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody. The biopharmaceutical company said findings from its research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.
2023-08-10 08:25:54 - Proactive Investors
Context Therapeutic says it has enough cash to fund operation into late 2024
Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has sufficient cash and cash equivalents to continue funding operations into late 2024.
2023-08-01 07:30:00 - GlobeNewsWire
Context Therapeutics to Participate in Two August 2023 Investor Conferences
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023. Details of the events are as follows:
2023-06-05 14:11:04 - Zacks Investment Research
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
2023-05-11 10:08:48 - Proactive Investors
Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024
Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's cash runway into late 2024. CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, is an immunotherapy designed to activate and direct a patient's own immune cells to CLDN6-positive tumors, including lung, ovarian, and testicular, the company noted.
2023-04-16 03:01:49 - Proactive Investors
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. The clinical-stage biopharmaceutical company said on April 17, 2023, at 4:30 PM EDT, it will host a webinar with its management team and AACR presenter, Dr Rucker, to discuss the results from this presentation, provide updates on the CTIM-76 preclinical program, and answer questions from investors.
2023-04-03 07:30:00 - GlobeNewsWire
Context Therapeutics to Participate in Two April 2023 Investor Conferences
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023. Details of the events are as follows:
2023-03-23 08:10:21 - Proactive Investors
Context Therapeutics announces pipeline update with FY 2022 financial results
Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024. Releasing its full-year 2022 financial statements, the Philadelphia-based women's oncology company said the resulting changes include discontinuing the development of onapristone extended-release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate.
2023-03-15 09:16:14 - Proactive Investors
Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting
Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. The clinical-stage biopharmaceutical company said on April 17, 2023, at 4:30 PM EDT, it will host a webinar with its management team and AACR presenter, Dr Rucker, to discuss the results from this presentation, provide updates on the CTIM-76 preclinical program, and answer questions from investors.